215 related articles for article (PubMed ID: 18804410)
1. Cetuximab in recurrent and/or metastatic salivary gland carcinomas: A phase II study.
Locati LD; Bossi P; Perrone F; Potepan P; Crippa F; Mariani L; Casieri P; Orsenigo M; Losa M; Bergamini C; Liberatoscioli C; Quattrone P; Calderone RG; Rinaldi G; Pilotti S; Licitra L
Oral Oncol; 2009 Jul; 45(7):574-8. PubMed ID: 18804410
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact.
Locati LD; Perrone F; Cortelazzi B; Bergamini C; Bossi P; Civelli E; Morosi C; Lo Vullo S; Imbimbo M; Quattrone P; Dagrada GP; Granata R; Resteghini C; Mirabile A; Alfieri S; Orlandi E; Mariani L; Saibene G; Pilotti S; Licitra L
Eur J Cancer; 2016 Dec; 69():158-165. PubMed ID: 27821319
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands.
Agulnik M; Cohen EW; Cohen RB; Chen EX; Vokes EE; Hotte SJ; Winquist E; Laurie S; Hayes DN; Dancey JE; Brown S; Pond GR; Lorimer I; Daneshmand M; Ho J; Tsao MS; Siu LL
J Clin Oncol; 2007 Sep; 25(25):3978-84. PubMed ID: 17761983
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical study of epidermal growth factor receptor in adenoid cystic carcinoma of salivary gland origin.
Vered M; Braunstein E; Buchner A
Head Neck; 2002 Jul; 24(7):632-6. PubMed ID: 12112535
[TBL] [Abstract][Full Text] [Related]
5. Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors.
Wong SJ; Karrison T; Hayes DN; Kies MS; Cullen KJ; Tanvetyanon T; Argiris A; Takebe N; Lim D; Saba NF; Worden FP; Gilbert J; Lenz HJ; Razak AR; Roberts JD; Vokes EE; Cohen EE
Ann Oncol; 2016 Feb; 27(2):318-23. PubMed ID: 26598548
[TBL] [Abstract][Full Text] [Related]
6. Epidermal growth factor receptor immunoexpression evaluation in malignant salivary gland tumours.
Monteiro LS; Bento MJ; Palmeira C; Lopes C
J Oral Pathol Med; 2009 Jul; 38(6):508-13. PubMed ID: 19317849
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of gefitinib in patients with advanced salivary gland cancers.
Jakob JA; Kies MS; Glisson BS; Kupferman ME; Liu DD; Lee JJ; El-Naggar AK; Gonzalez-Angulo AM; Blumenschein GR
Head Neck; 2015 May; 37(5):644-9. PubMed ID: 24585506
[TBL] [Abstract][Full Text] [Related]
8. Clinical trial of nintedanib in patients with recurrent or metastatic salivary gland cancer of the head and neck: A multicenter phase 2 study (Korean Cancer Study Group HN14-01).
Kim Y; Lee SJ; Lee JY; Lee SH; Sun JM; Park K; An HJ; Cho JY; Kang EJ; Lee HY; Kim J; Keam B; Kim HR; Lee KE; Choi MY; Lee KH; Ahn MJ
Cancer; 2017 Jun; 123(11):1958-1964. PubMed ID: 28102887
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of cisplatin and imatinib in advanced salivary adenoid cystic carcinoma.
Ghosal N; Mais K; Shenjere P; Julyan P; Hastings D; Ward T; Ryder WD; Bruce I; Homer J; Slevin NJ
Br J Oral Maxillofac Surg; 2011 Oct; 49(7):510-5. PubMed ID: 21071117
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer.
Hanna N; Lilenbaum R; Ansari R; Lynch T; Govindan R; Jänne PA; Bonomi P
J Clin Oncol; 2006 Nov; 24(33):5253-8. PubMed ID: 17114658
[TBL] [Abstract][Full Text] [Related]
11. Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab.
Lv S; Teugels E; Sadones J; De Brakeleer S; Duerinck J; Du Four S; Michotte A; De Grève J; Neyns B
Int J Oncol; 2012 Sep; 41(3):1029-35. PubMed ID: 22752145
[TBL] [Abstract][Full Text] [Related]
12. Cetuximab shows activity in colorectal cancer patients with tumors for which FISH analysis does not detect an increase in EGFR gene copy number.
Italiano A; Follana P; Caroli FX; Badetti JL; Benchimol D; Garnier G; Gugenheim J; Haudebourg J; Keslair F; Lesbats G; Lledo G; Roussel JF; Pedeutour F; François E
Ann Surg Oncol; 2008 Feb; 15(2):649-54. PubMed ID: 17987340
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of cyclin D1 and cortactin is primarily independent of gene amplification in salivary gland adenoid cystic carcinoma.
Greer RO; Said S; Shroyer KR; Marileila VG; Weed SA
Oral Oncol; 2007 Sep; 43(8):735-41. PubMed ID: 17113340
[TBL] [Abstract][Full Text] [Related]
14. Molecular differences in mucoepidermoid carcinoma and adenoid cystic carcinoma of the major salivary glands.
Gibbons MD; Manne U; Carroll WR; Peters GE; Weiss HL; Grizzle WE
Laryngoscope; 2001 Aug; 111(8):1373-8. PubMed ID: 11568571
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor--its expression and copy numbers of EGFR gene in patients with head and neck squamous cell carcinomas.
Mrhalova M; Plzak J; Betka J; Kodet R
Neoplasma; 2005; 52(4):338-43. PubMed ID: 16059652
[TBL] [Abstract][Full Text] [Related]
16. Imatinib mesylate in patients with adenoid cystic cancers of the salivary glands expressing c-kit: a Princess Margaret Hospital phase II consortium study.
Hotte SJ; Winquist EW; Lamont E; MacKenzie M; Vokes E; Chen EX; Brown S; Pond GR; Murgo A; Siu LL
J Clin Oncol; 2005 Jan; 23(3):585-90. PubMed ID: 15659505
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial with axitinib in recurrent and/or metastatic salivary gland cancers of the upper aerodigestive tract.
Locati LD; Cavalieri S; Bergamini C; Resteghini C; Alfieri S; Calareso G; Bossi P; Perrone F; Tamborini E; Quattrone P; Granata R; Galbiati D; Platini F; Orlandi E; Mariani L; Licitra L
Head Neck; 2019 Oct; 41(10):3670-3676. PubMed ID: 31355973
[TBL] [Abstract][Full Text] [Related]
18. Salivary gland adenoid cystic carcinoma: a review of chemotherapy and molecular therapies.
Dodd RL; Slevin NJ
Oral Oncol; 2006 Sep; 42(8):759-69. PubMed ID: 16757203
[TBL] [Abstract][Full Text] [Related]
19. [Molecularly targeted therapy in head and neck cancer].
Le Tourneau C
Bull Cancer; 2010 Dec; 97(12):1453-66. PubMed ID: 21134823
[TBL] [Abstract][Full Text] [Related]
20. EGFR fluorescence in situ hybridization pattern of chromosome 7 disomy predicts resistance to cetuximab in KRAS wild-type metastatic colorectal cancer patients.
Li YH; Wang F; Shen L; Deng YM; Shao Q; Feng F; An X; Wang FH; Wang ZQ; Xu RH; Shao JY
Clin Cancer Res; 2011 Jan; 17(2):382-90. PubMed ID: 20884623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
